Arcturus Therapeutics (ARCT) CFO granted 100,000 stock options

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. reported that its Chief Financial Officer, Dennis Mulroy, received a grant of employee stock options covering 100,000 shares of common stock. These options have an exercise price of $8.63 per share and expire on May 1, 2036.

The grant was made under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan as part of equity compensation. The underlying shares vest 25% on May 1, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, encouraging longer-term alignment with shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MULROY DENNIS

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	100,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 100,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Key Figures

Option grant size: 100,000 options Exercise price: $8.63 per share Expiration date: May 1, 2036 +2 more

5 metrics

Option grant size 100,000 options Employee stock options granted to CFO Dennis Mulroy

Exercise price $8.63 per share Exercise price for the granted employee stock options

Expiration date May 1, 2036 Option expiration for the CFO’s 100,000 options

Initial vesting tranche 25% on May 1, 2027 First vesting event, one year after grant date

Remaining vesting period 36 monthly installments Remaining 75% vests in equal monthly increments

Key Terms

Employee Stock Option (right to buy), Amended and Restated 2019 Omnibus Equity Incentive Plan, vest

3 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

Amended and Restated 2019 Omnibus Equity Incentive Plan financial

"granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended."

vest financial

"The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MULROY DENNIS

(Last) (First) (Middle)

C/O ARCTURUS THERAPEUTICS HOLDINGS INC.

10285 SCIENCE CENTER DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$8.63	05/01/2026		A		100,000(1)		(2)	05/01/2036	Common Stock	100,000	$0.00	100,000	D

Explanation of Responses:

1. Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

2. The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

	/s/ Grant Levine, as attorney-in-fact for Dennis Mulroy	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Arcturus Therapeutics (ARCT) report for its CFO?

Arcturus Therapeutics reported that CFO Dennis Mulroy received a grant of 100,000 employee stock options. These options give him the right to buy common shares at a fixed $8.63 exercise price, expiring on May 1, 2036, as part of his equity compensation package.

What is the exercise price of the CFO’s new Arcturus (ARCT) stock options?

The granted stock options have an exercise price of $8.63 per share. This means the CFO can purchase Arcturus common stock at $8.63, regardless of future market price, once the options vest, subject to the plan’s terms and the stated vesting schedule.

How many Arcturus (ARCT) stock options were granted to the CFO?

The CFO received 100,000 employee stock options linked to Arcturus common stock. All 100,000 options were reported as directly held following the transaction, reflecting a single equity award under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan.

What is the vesting schedule for the Arcturus (ARCT) CFO’s option grant?

The stock options vest 25% on May 1, 2027, which is the first anniversary of the grant date. The remaining 75% then vests in equal installments on each monthly anniversary for the next 36 months, creating a four-year total vesting period from the grant date.

Under which plan were the Arcturus (ARCT) CFO’s stock options granted?

The options were granted under Arcturus Therapeutics’ Amended and Restated 2019 Omnibus Equity Incentive Plan. This plan authorizes equity-based awards, such as stock options, to employees and executives as part of their long-term incentive and retention compensation.